Artemis Investment Management LLP grew its holdings in Humana Inc (NYSE:HUM) by 136.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 202,194 shares of the insurance provider’s stock after acquiring an additional 116,778 shares during the period. Artemis Investment Management LLP’s holdings in Humana were worth $51,574,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Maverick Capital Ltd. boosted its holdings in shares of Humana by 150.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock worth $411,408,000 after buying an additional 932,778 shares during the period. Nuveen Asset Management LLC boosted its holdings in shares of Humana by 4,141.9% during the 2nd quarter. Nuveen Asset Management LLC now owns 706,911 shares of the insurance provider’s stock worth $187,543,000 after buying an additional 690,246 shares during the period. PointState Capital LP bought a new stake in shares of Humana during the 2nd quarter worth $180,507,000. Marshall Wace North America L.P. boosted its holdings in shares of Humana by 6,921.1% during the 2nd quarter. Marshall Wace North America L.P. now owns 536,275 shares of the insurance provider’s stock worth $142,273,000 after buying an additional 528,637 shares during the period. Finally, Point72 Asset Management L.P. bought a new stake in shares of Humana during the 2nd quarter worth $115,680,000. 92.77% of the stock is owned by institutional investors.
In other news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total value of $2,097,138.30. Following the completion of the transaction, the insider now owns 12,994 shares in the company, valued at approximately $3,764,361.80. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.54% of the company’s stock.
Several analysts recently issued reports on the stock. Cantor Fitzgerald raised shares of Humana from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $300.00 to $345.00 in a report on Monday, August 12th. Morgan Stanley cut their target price on shares of Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a research note on Thursday, September 26th. JPMorgan Chase & Co. upped their target price on shares of Humana from $288.00 to $322.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. Deutsche Bank initiated coverage on shares of Humana in a research note on Thursday, September 12th. They set a “hold” rating and a $300.00 target price for the company. Finally, Piper Jaffray Companies upped their target price on shares of Humana from $315.00 to $341.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $334.21.
Shares of HUM stock traded up $6.86 during mid-day trading on Thursday, reaching $260.66. The company’s stock had a trading volume of 675,301 shares, compared to its average volume of 1,073,191. Humana Inc has a 1-year low of $225.65 and a 1-year high of $355.88. The company has a market cap of $34.48 billion, a P/E ratio of 17.91, a PEG ratio of 1.10 and a beta of 0.83. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. The firm’s 50-day moving average is $273.18 and its two-hundred day moving average is $267.00.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.24 by $0.81. Humana had a net margin of 4.13% and a return on equity of 22.47%. The company had revenue of $16.25 billion during the quarter, compared to analysts’ expectations of $15.88 billion. During the same quarter in the prior year, the company posted $3.96 EPS. The business’s revenue was up 13.9% on a year-over-year basis. Sell-side analysts anticipate that Humana Inc will post 17.67 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date is Friday, September 27th. Humana’s dividend payout ratio is 15.12%.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Arbitrage
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.